PFM
STOK icon

Privium Fund Management’s Stoke Therapeutics STOK Stock Holding History

Privium Fund Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$1.63M – 69
2026
Q1 		$1.63M Sell
50,000
-5,000
-9% -$164K 0.34% 36
2025
Q4 		$1.75M Buy
+55,000
New +$1.65M 0.32% 34

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Privium Fund Management's STOK Position: Q2 2026 in Review

Privium Fund Management sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 50,000 shares — an estimated $1.63M sold.

Privium Fund Management first reported a position in STOK in Q4 2025 and held it in 2 quarters. The position peaked at $1.75M in Q4 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Privium Fund Management reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Privium Fund Management sold 50,000 Stoke Therapeutics shares in Q2 2026, an estimated $1.63M.
  • Privium Fund Management first reported a position in Stoke Therapeutics in Q4 2025 and held it in 2 quarters.
  • Privium Fund Management's Stoke Therapeutics position peaked at $1.75M in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.